GeoPharma gained notoriety in 2004 when it issued a press release misleadingly claiming FDA approval for a new prescription product to treat the side effects of chemotherapy and radiation
Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi MG, et al
The inhibition of SGLT2 improves hyperglycemia hampering urinary reabsorption of glucose and inducing glycosuria
Though people have shared personal stories of the medications sometimes surprising side effects, such as pregnancy, and individual studies have hinted at new benefits and risks, there have been few studies that have been able to take a comprehensive look at how these medications, which include Ozempic, Wegovy, Mounjaro and Zepbound, may change a persons overall health
Fixed pricing regardless of the dosage
In a recently completed phase 2 trial (abstract data), 46 weeks of survodutide once weekly (0.6 to 4.8 mg) resulted in a dose-dependent mean WL up to 18.7% vs